The immune system can recognize self antigens expressed by cancer cells. Differentiation antigens are prototypes of these self antigens, being expressed by cancer cells and their normal cell counterparts. The tyrosinase family proteins are well characterized differentiation antigens recognized by antibodies and T cells of patients with melanoma. However, immune tolerance may prevent immunity directed against these antigens. Immunity to the brown locus protein, gp75/ tyrosinase-related protein-1, was investigated in a syngeneic mouse model. C57BL/6 mice, which are tolerant to gp75, generated autoantibodies against gp75 after immunization with DNA encoding human gp75 but not syngeneic mouse gp75. Priming with human gp75 DNA broke tolerance to mouse gp75. Immunity against mouse gp75 provided significant tumor protection. Manifestations of autoimmunity were observed, characterized by coat depigmentation. Rejection of tumor challenge required CD4(+) and NK1.1(+) cells and Fc receptor gamma-chain, but depigmentation did not require these components. Thus, immunization with homologous DNA broke tolerance against mouse gp75, possibly by providing help from CD4(+) T cells. Mechanisms required for tumor protection were not necessary for autoimmunity, demonstrating that tumor immunity can be uncoupled from autoimmune manifestations.
L W Weber, W B Bowne, J D Wolchok, R Srinivasan, J Qin, Y Moroi, R Clynes, P Song, J J Lewis, A N Houghton
Title and authors | Publication | Year |
---|---|---|
Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma
G Ghanem, J Fabrice |
Molecular Oncology | 2011 |
Autoimmunity associated with immunotherapy of cancer
SM Amos, CP Duong, JA Westwood, DS Ritchie, RP Junghans, PK Darcy, MH Kershaw |
Blood | 2011 |
Advances in Immunology
E Pinaud, M Marquet, R Fiancette, S Péron, C Vincent-Fabert, Y Denizot, M Cogné |
Advances in Immunology Volume 110 | 2011 |
Cancer Vaccines: From Research to Clinical Practice
B Jin, AE Yeo |
Cancer Vaccines: From Research to Clinical Practice | 2011 |
Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice
F Orlandi, JA Guevara-Patiño, T Merghoub, JD Wolchok, AN Houghton, PD Gregor |
Vaccine | 2011 |
Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma
G Ghanem, J Fabrice |
Molecular Oncology | 2011 |
Chicken HSP70 DNA vaccine inhibits tumor growth in a canine cancer model
WY Yu, TF Chuang, C Guichard, H El-Garch, D Tierny, AT Laio, CS Lin, KH Chiou, CL Tsai, CH Liu, WC Li, L Fischer, RM Chu |
Vaccine | 2011 |
Advances in Cancer Research
M Lemaire, S Deleu, ED Bruyne, EV Valckenborgh, E Menu, K Vanderkerken |
Advances in Cancer Research Volume 110 | 2011 |
Oncolytic plasmid: A novel strategy for tumor immuno-gene therapy
C Yoshihara, K Hamada, M Kuroda, Y Koyama |
Oncology Letters | 2011 |
Beyond Cancer Vaccines: A Reason for Future Optimism with Immunomodulatory Therapy
M Postow, MK Callahan, JD Wolchok |
Cancer journal (Sudbury, Mass.) | 2011 |
Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor
DA Grosenbaugh, AT Leard, PJ Bergman, MK Klein, K Meleo, S Susaneck, PR Hess, MK Jankowski, PD Jones, NF Leibman, MH Johnson, ID Kurzman, JD Wolchok |
American Journal of Veterinary Research | 2011 |